Third Rock Ventures IV, L.P. 13D and 13G filings for Tango Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-10 4:15 pm Sale | 2026-02-06 | 13D | Tango Therapeutics, Inc. TNGX | Third Rock Ventures IV, L.P. | 6,374,574 4.740% | -1,500,000 (-19.05%) | Filing |
| 2025-11-21 4:15 pm Sale | 2025-11-19 | 13D | Tango Therapeutics, Inc. TNGX | Third Rock Ventures IV, L.P. | 7,874,574 5.850% | -1,500,000 (-16.00%) | Filing |
| 2025-11-14 4:15 pm Sale | 2025-11-12 | 13D | Tango Therapeutics, Inc. TNGX | Third Rock Ventures IV, L.P. | 9,374,574 6.970% | -7,626,901 (-44.86%) | Filing |
| 2024-09-04 8:45 pm Sale | 2024-08-30 | 13D | Tango Therapeutics, Inc. TNGX | Third Rock Ventures IV, L.P. | 17,001,475 15.900% | -2,362,500 (-12.20%) | Filing |
| 2021-08-19 4:35 pm Purchase | 2021-08-10 | 13D | Tango Therapeutics, Inc. TNGX | Third Rock Ventures IV, L.P. | 19,363,975 22.100% | 19,363,975 (New Position) | Filing |